390 related articles for article (PubMed ID: 26126965)
41. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis.
Italiani P; Carlesi C; Giungato P; Puxeddu I; Borroni B; Bossù P; Migliorini P; Siciliano G; Boraschi D
J Neuroinflammation; 2014 May; 11():94. PubMed ID: 24884937
[TBL] [Abstract][Full Text] [Related]
42. Evaluating the levels of CSF and serum factors in ALS.
Guo J; Yang X; Gao L; Zang D
Brain Behav; 2017 Mar; 7(3):e00637. PubMed ID: 28293476
[TBL] [Abstract][Full Text] [Related]
43. Serum asymmetric dimethylarginine level correlates with the progression and prognosis of amyotrophic lateral sclerosis.
Ikenaka K; Maeda Y; Hotta Y; Nagano S; Yamada S; Ito D; Torii R; Kakuda K; Tatebe H; Atsuta N; Aguirre C; Kimura Y; Baba K; Tokuda T; Katsuno M; Kimura K; Sobue G; Mochizuki H
Eur J Neurol; 2022 May; 29(5):1410-1416. PubMed ID: 35128793
[TBL] [Abstract][Full Text] [Related]
44. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression.
Murdock BJ; Zhou T; Kashlan SR; Little RJ; Goutman SA; Feldman EL
JAMA Neurol; 2017 Dec; 74(12):1446-1454. PubMed ID: 28973548
[TBL] [Abstract][Full Text] [Related]
45. Exploring the Role of Metabolic Hormones in Amyotrophic Lateral Sclerosis.
Moțățăianu A; Mănescu IB; Șerban G; Bărcuțean L; Ion V; Bălașa R; Andone S
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791099
[TBL] [Abstract][Full Text] [Related]
46. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis.
Ono S; Hu J; Shimizu N; Imai T; Nakagawa H
J Neurol Sci; 2001 Jun; 187(1-2):27-34. PubMed ID: 11440741
[TBL] [Abstract][Full Text] [Related]
47. Elimination Rate of Serum Lactate is Correlated with Amyotrophic Lateral Sclerosis Progression.
Zhang YJ; Fan DS
Chin Med J (Engl); 2016 Jan; 129(1):28-32. PubMed ID: 26712429
[TBL] [Abstract][Full Text] [Related]
48. Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis--A Pilot Study.
Maier A; Deigendesch N; Müller K; Weishaupt JH; Krannich A; Röhle R; Meissner F; Molawi K; Münch C; Holm T; Meyer R; Meyer T; Zychlinsky A
PLoS One; 2015; 10(10):e0139684. PubMed ID: 26444282
[TBL] [Abstract][Full Text] [Related]
49. [Surface CD2, CD4, CD8 markers and IL-2 and TNF-alpha cytokines in amyotrophic lateral sclerosis].
Losy J; Michałowska-Wender G
Neurol Neurochir Pol; 2001; 35(1):57-61. PubMed ID: 11464717
[TBL] [Abstract][Full Text] [Related]
50. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis.
Keizman D; Rogowski O; Berliner S; Ish-Shalom M; Maimon N; Nefussy B; Artamonov I; Drory VE
Acta Neurol Scand; 2009 Jun; 119(6):383-9. PubMed ID: 18976328
[TBL] [Abstract][Full Text] [Related]
51. Can Oxidation-Reduction Potential of Cerebrospinal Fluid Be a Monitoring Biomarker in Amyotrophic Lateral Sclerosis?
Opačić M; Stević Z; Baščarević V; Živić M; Spasić M; Spasojević I
Antioxid Redox Signal; 2018 Jun; 28(17):1570-1575. PubMed ID: 29113448
[TBL] [Abstract][Full Text] [Related]
52. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia?
Moreau C; Devos D; Brunaud-Danel V; Defebvre L; Perez T; Destée A; Tonnel AB; Lassalle P; Just N
Neurology; 2005 Dec; 65(12):1958-60. PubMed ID: 16380619
[TBL] [Abstract][Full Text] [Related]
53. Blood Cell Palmitoleate-Palmitate Ratio Is an Independent Prognostic Factor for Amyotrophic Lateral Sclerosis.
Henriques A; Blasco H; Fleury MC; Corcia P; Echaniz-Laguna A; Robelin L; Rudolf G; Lequeu T; Bergaentzle M; Gachet C; Pradat PF; Marchioni E; Andres CR; Tranchant C; Gonzalez De Aguilar JL; Loeffler JP
PLoS One; 2015; 10(7):e0131512. PubMed ID: 26147510
[TBL] [Abstract][Full Text] [Related]
54. Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS.
Brodovitch A; Boucraut J; Delmont E; Parlanti A; Grapperon AM; Attarian S; Verschueren A
Sci Rep; 2021 Jan; 11(1):703. PubMed ID: 33436881
[TBL] [Abstract][Full Text] [Related]
55. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials.
Witzel S; Frauhammer F; Steinacker P; Devos D; Pradat PF; Meininger V; Halbgebauer S; Oeckl P; Schuster J; Anders S; Dorst J; Otto M; Ludolph AC
Transl Neurodegener; 2021 Aug; 10(1):31. PubMed ID: 34433481
[TBL] [Abstract][Full Text] [Related]
56. Identification of erythrocyte biomarkers in amyotrophic lateral sclerosis.
Lima C; Pinto S; Napoleão P; Pronto-Laborinho AC; Barros MA; Freitas T; de Carvalho M; Saldanha C
Clin Hemorheol Microcirc; 2016 Oct; 63(4):423-437. PubMed ID: 27258202
[TBL] [Abstract][Full Text] [Related]
57. Plasma cortisol level in amyotrophic lateral sclerosis.
Spataro R; Volanti P; Vitale F; Meli F; Colletti T; Di Natale A; La Bella V
J Neurol Sci; 2015 Nov; 358(1-2):282-6. PubMed ID: 26384616
[TBL] [Abstract][Full Text] [Related]
58. The serum lipid profiles of amyotrophic lateral sclerosis patients: A study from south-west China and a meta-analysis.
Huang R; Guo X; Chen X; Zheng Z; Wei Q; Cao B; Zeng Y; Shang H
Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(5-6):359-65. PubMed ID: 26121273
[TBL] [Abstract][Full Text] [Related]
59. Decreased serum endoglin level in patients with amyotrophic lateral sclerosis: a preliminary report.
Iłzecka J
Scand J Clin Lab Invest; 2008; 68(4):348-51. PubMed ID: 17852832
[TBL] [Abstract][Full Text] [Related]
60. C-reactive protein levels in patients with amyotrophic lateral sclerosis: A systematic review.
Kharel S; Ojha R; Preethish-Kumar V; Bhagat R
Brain Behav; 2022 Mar; 12(3):e2532. PubMed ID: 35201675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
